Evidence map›Paper›PMID 41179597›Full record

ArticleClinical case reports2025

Hepatoid Adenocarcinoma of the Stomach Combined With Gastric Neuroendocrine Carcinoma: A Case Report.

Banghui Ma, Ping Zheng, Yongdong Jin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Banghui MaDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine University of Electronic Science and Technology of China Chengdu China.ORCID https://orcid.org/0009-0000-6409-6636
Ping ZhengDepartment of Pathology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center University of Electronic Science and Technology of China Chengdu China.
Yongdong JinDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center University of Electronic Science and Technology of China Chengdu China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Both hepatoid adenocarcinoma of the stomach (HAS) and gastric neuroendocrine carcinoma (NEC) are rare subtypes of gastric cancer, characterized by aggressive behavior and poor prognosis, for which no definitive treatment regimen has been established to date. A 56-year-old male was diagnosed with HAS combined with NEC, accompanied by perigastric lymph node and liver metastases. Initially, he received EP chemotherapy, which was subsequently switched to a regimen of capecitabine plus oxaliplatin due to insufficient therapeutic response. Ultimately, the treatment was transitioned to a combination of immunotherapy and targeted therapy with Lenvatinib plus Envafolimab, owing to the development of capecitabine intolerance. The optimal management of this disease remains undefined, and conventional chemotherapy often results in suboptimal outcomes. However, in this case, the treatment with Lenvatinib plus Envafolimab appears to be an effective strategy for prolonging survival time and improving quality of life. Further experimental and clinical investigations are warranted to validate these findings and substantiate this therapeutic hypothesis.

Indexed as

case reportgastric neuroendocrine carcinomahepatoid adenocarcinoma of the stomachimmunotherapyliver metastasistargeted therapy

Identifiers

PMID41179597
PMCPMC12576141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.